Emergent Biosolutions (EBS) Stock Price, Quote & News

Company Profile

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax va...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 240 631 3200

Website: www.emergentbiosolutions.com

Address:

300 Professional Drive, Gaithersburg, United States

Kazoonova Jul. 15 at 10:19 PM

$EBS Obligatory 'I hate these board members' message.

0 · Reply

KnuckleSandwich Jul. 15 at 9:43 PM

$EBS For the smart few that loaded shares today....you will be enjoying nice profits by end of week...tomorrow on open may be a small window to buy more under 7 but news is coming and double digits are in the future for EBS.

0 · Reply

zredpill Jul. 15 at 9:25 PM

$EBS charge your phone, imo

0 · Reply

ComradeKomisar Jul. 15 at 9:12 PM

$EBS it is of interest to note: apparently, one is in "blackout" only when it comes to buying 😕

0 · Reply

WinstonSmith33 Jul. 15 at 8:43 PM

$EBS oh, so the season has started. I bet the next one will be: Poor Rich. Still too low salary to buy even one share.

0 · Reply

ComradeKomisar Jul. 15 at 8:40 PM

$EBS god forbid people would sell some of their largest asset to pay tax.

1 · Reply

billywilliamz Jul. 15 at 8:13 PM

$EBS not good Insiders disposing. Back to 4.50

2 · Reply

KnuckleSandwich Jul. 15 at 7:47 PM

$EBS @NRG8 does not like to be checked...but he is plenty happy to offer advice without any skin in the game..????..if you are so confident step up and put your money to work!...everyone can be a winner.

0 · Reply

KnuckleSandwich Jul. 15 at 7:39 PM

$EBS How cool would it be if Papa brought us another nice surprise from the insiders...?

0 · Reply

KnuckleSandwich Jul. 15 at 7:01 PM

$EBS another 2K at 6.91....this will be bouncing nicely by end of week.

0 · Reply

Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025

Jul 8, 2025, 4:45 PM EDT - 7 days ago

Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense Preparedness Efforts

Jul 2, 2025, 4:05 PM EDT - 13 days ago

Emergent BioSolutions Expands NARCANDirect® to Offer KLOXXADO® (naloxone HCl) Nasal Spray 8 mg and Convenience Kits Amid Changes in Overdose Death Rate

Jun 23, 2025, 8:05 AM EDT - 22 days ago

Emergent BioSolutions Secures $62.4 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Bolster U.S. Biodefense Supply

Jun 20, 2025, 2:25 PM EDT - 25 days ago

Emergent BioSolutions: Strategic Turnaround Proving Tricky, But I'm Still Hopeful

Jun 20, 2025, 8:13 AM EDT - 25 days ago

Emergent BioSolutions Announces Addition to Russell 3000® Index

Jun 5, 2025, 7:00 AM EDT - 5 weeks ago

Emergent BioSolutions Supports Victoria's Voice Foundation's National Naloxone Awareness Day Efforts on June 6 to Encourage Americans to Be Prepared for Opioid Emergencies

May 14, 2025, 7:32 AM EDT - 2 months ago

Emergent BioSolutions to Participate in Upcoming Investor Conferences

May 7, 2025, 10:01 PM EDT - 2 months ago

Emergent BioSolutions Inc. (EBS) Q1 2025 Earnings Call Transcript

May 7, 2025, 4:05 PM EDT - 2 months ago

Emergent BioSolutions Reports First Quarter 2025 Financial Results

May 1, 2025, 5:07 PM EDT - 2 months ago

Emergent BioSolutions Reinforces Commitment to Opioid Emergency Preparedness Efforts in Canada Through Multi-Year Contract with Ontario Ministry of Health

Apr 22, 2025, 8:00 AM EDT - 3 months ago

Emergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025

Mar 31, 2025, 8:00 AM EDT - 3 months ago

Emergent BioSolutions Announces Stock Repurchase Program

Mar 20, 2025, 4:30 PM EDT - 4 months ago

Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08

Mar 20, 2025, 8:06 AM EDT - 4 months ago

Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg

Mar 19, 2025, 4:30 PM EDT - 4 months ago

Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International

Mar 18, 2025, 8:00 AM EDT - 4 months ago

Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products

Mar 13, 2025, 8:29 AM EDT - 4 months ago

Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs

Mar 12, 2025, 8:00 AM EDT - 4 months ago

Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates

Mar 10, 2025, 9:14 AM EDT - 4 months ago

Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International

Mar 3, 2025, 7:58 PM EST - 4 months ago

Emergent BioSolutions Inc. (EBS) Q4 2024 Earnings Call Transcript

Mar 3, 2025, 4:23 PM EST - 4 months ago

Emergent BioSolutions Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 18, 2025, 8:55 AM EST - 5 months ago

Emergent BioSolutions to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

Feb 7, 2025, 8:06 AM EST - 5 months ago

Emergent BioSolutions and Pro Football Legend Emmitt Smith Raise Awareness of Ready to Rescue Campaign Timed to the Big Game in New Orleans

Jan 16, 2025, 8:00 AM EST - 6 months ago

Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)

Jan 14, 2025, 7:53 AM EST - 6 months ago

Emergent BioSolutions: Stock Is A Likely Winner In 2025

Jan 14, 2025, 7:30 AM EST - 6 months ago

Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO® (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals

Jan 13, 2025, 9:27 AM EST - 6 months ago

Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration with BARDA on Ebanga™ (ansuvimab-zykl) Treatment for Ebola

Jan 8, 2025, 7:45 AM EST - 6 months ago

Emergent BioSolutions to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025

Jan 8, 2025, 7:30 AM EST - 6 months ago

Emergent BioSolutions Announces Exercise of $20 Million Option to Supply U.S. Department of Defense with BioThrax® (Anthrax Vaccine Adsorbed)

Dec 2, 2024, 5:49 PM EST - 8 months ago

SIGA Technologies Vs Emergent BioSolutions: Product Portfolio And Future Outlook

SIGA

Nov 8, 2024, 9:25 AM EST - 8 months ago

Emergent BioSolutions: Stock Surging Post Q3 Earnings Thanks To Papa Magic

Nov 7, 2024, 2:06 PM EST - 8 months ago

Mpox Vaccine Player Emergent BioSolutions Stock Jumps On Upbeat Annual Forecast, Expects Smaller Losses In 2024

Nov 6, 2024, 10:08 PM EST - 8 months ago

Emergent BioSolutions Inc. (EBS) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:49 PM EST - 8 months ago

Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa

Oct 23, 2024, 7:30 AM EDT - 9 months ago

Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference Call on November 6, 2024

Oct 8, 2024, 5:32 PM EDT - 10 months ago

Emergent BioSolutions Demonstrates Commitment to Increasing Access & Awareness of NARCAN® Nasal Spray to Help Combat the Opioid Epidemic

Oct 4, 2024, 9:48 AM EDT - 10 months ago

Emergent BioSolutions: Strategic Shifts Present A Turnaround Scenario

Sep 26, 2024, 8:05 AM EDT - 10 months ago

Emergent BioSolutions Announces the Execution of Contract Options Valued at $67.4 Million to Procure Additional TEMBEXA® (brincidofovir) to Support National Preparedness Efforts

Sep 25, 2024, 10:33 AM EDT - 10 months ago

Emergent BioSolutions Confirms Orders Worth $400M Related To Smallpox, Mpox Vaccines

Sep 25, 2024, 7:07 AM EDT - 10 months ago

Emergent BioSolutions Confirms Approximately $400 million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness Efforts

Sep 12, 2024, 8:30 AM EDT - 10 months ago

Emergent BioSolutions Awarded Research and Development Option valued at $41.9 Million for continued Advanced Development and Procurement of Ebanga™ Treatment for Ebola

Sep 3, 2024, 7:08 AM EDT - 11 months ago

Emergent BioSolutions Successfully Refinances Debt & Further Strengthens Financial Profile

Aug 30, 2024, 6:45 PM EDT - 11 months ago

Upside for Emergent Bio if they can get Mpox vaccine rollout right, says Mizuho's Jared Holz

Aug 30, 2024, 8:16 AM EDT - 11 months ago

Emergent BioSolutions Expands Ready to Rescue Initiative to Support Widespread Opioid Emergency Preparedness

Aug 30, 2024, 7:43 AM EDT - 11 months ago

Mpox Vaccine: Emergent BioSolutions' Smallpox Vaccine Gets FDA Nod For Expanded Use For Individuals At High Risk Of Mpox Infection

Aug 30, 2024, 7:15 AM EDT - 11 months ago

Emergent BioSolutions Stock Soars as FDA Approves Mpox Vaccine

Aug 29, 2024, 7:21 PM EDT - 11 months ago

US FDA approves use of Emergent's smallpox vaccine for people at high risk of mpox

Aug 29, 2024, 6:53 PM EDT - 11 months ago

Emergent BioSolutions' ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) Receives U.S. FDA Approval for Mpox Indication; Public Health Mpox Outbreak Continues Across Africa & Other Regions

Aug 20, 2024, 11:30 AM EDT - 11 months ago

Emergent BioSolutions Finalizes Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals

Kazoonova Jul. 15 at 10:19 PM

$EBS Obligatory 'I hate these board members' message.

0 · Reply

KnuckleSandwich Jul. 15 at 9:43 PM

0 · Reply

zredpill Jul. 15 at 9:25 PM

$EBS charge your phone, imo

0 · Reply

ComradeKomisar Jul. 15 at 9:12 PM

$EBS it is of interest to note: apparently, one is in "blackout" only when it comes to buying 😕

0 · Reply

WinstonSmith33 Jul. 15 at 8:43 PM

$EBS oh, so the season has started. I bet the next one will be: Poor Rich. Still too low salary to buy even one share.

0 · Reply

ComradeKomisar Jul. 15 at 8:40 PM

$EBS god forbid people would sell some of their largest asset to pay tax.

1 · Reply

billywilliamz Jul. 15 at 8:13 PM

$EBS not good Insiders disposing. Back to 4.50

2 · Reply

KnuckleSandwich Jul. 15 at 7:47 PM

0 · Reply

KnuckleSandwich Jul. 15 at 7:39 PM

$EBS How cool would it be if Papa brought us another nice surprise from the insiders...?

0 · Reply

KnuckleSandwich Jul. 15 at 7:01 PM

$EBS another 2K at 6.91....this will be bouncing nicely by end of week.

0 · Reply

Joelojr Jul. 15 at 6:58 PM

$EBS thoughts on er coming Aug 6 ? feel good? @KnuckleSandwich @Ithaca2018 considering pickin' some. Best to all.

2 · Reply

ComradeKomisar Jul. 15 at 6:49 PM

$EBS this seems like a shart attack to me (XBI in yellow)

0 · Reply

KnuckleSandwich Jul. 15 at 6:45 PM

$EBS take the opportunity on this market down day to load up...the next news cycle is going t move EBS up big!

0 · Reply

Ithaca2018 Jul. 15 at 6:45 PM

$EBS Okay, If this goes down to $6.66 I'm gonna go in big! Big for me is like 500 Shares.... LOL!

0 · Reply

IntelligunInvestings Jul. 15 at 6:42 PM

$EBS buying under my avg👍 keep it up shorts You only make the price more attractive

0 · Reply

KnuckleSandwich Jul. 15 at 6:39 PM

$EBS bought 2K more at 6.99

0 · Reply

Ithaca2018 Jul. 15 at 6:37 PM

$EBS Bought 200 more $6.98 Crazy!

0 · Reply

tienvo Jul. 15 at 6:29 PM

$EBS I am done buying today

1 · Reply

billywilliamz Jul. 15 at 6:23 PM

$EBS ngr7

1 · Reply

ComradeKomisar Jul. 15 at 5:37 PM

$EBS Anyone have an idea who has this $0.67 EPS call for Q2? It's skewing the average to (-$0.10)

2 · Reply

zredpill Jul. 15 at 5:21 PM

$EBS yes, but we have debt, just started showing profitability, we aren’t show much growth yet and we are part of the Russell 3000. It’s a stock with hairs and market doesn’t like that

3 · Reply

ComradeKomisar Jul. 15 at 5:11 PM

$EBS Sure, but we're not dependent on the 'economy'.

0 · Reply

Market Cap	399.49M
Revenue (ttm)	1.04B
Net Income (ttm)	-190.60M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	10.78
Profit Margin	-18.26%
Debt to Equity Ratio	1.20

Volume	895,631
Avg Vol	1,341,866
Day's Range	N/A - N/A
Shares Out	54.28M
Stochastic %K	76%
Beta	2.09
Analysts	Sell
Price Target	$13.50